DVT

Is managed care overusing inferior vena cava filters?A new study evaluating Humana claims data reveals interesting findings about IVC filter use in managed care.
Compression stockings, AF patients at risk, and ICH outcomesAnticoagulation briefs.
Pre-op anticoagulation reduces VTE risk in cancer patientsResearchers found that rates of DVT and PE were significantly lower among patients who received preoperative chemoprophylaxis than in those who did not.
Less bleeding with rivaroxaban for venous thromboembolismStudies involving more than 8,000 patients found that rivaroxaban beat out low-molecular-weight heparin/vitamin K antagonists with fewer and less challenging bleeding episodes.
Limb gangrene in cancer patients receiving warfarinVenous limb gangrene can occur in cancer patients, but the clinical picture and pathogenesis aren’t clear.
Dual antiplatelet therapy lowers risk of CV death in MI secondary preventionSecondary prevention of MI still calls for a careful balancing act between risks and benefits.
DVT patients taking rivaroxaban had fewer hospital admissions, costs, similar subsequent hospital visits vs. standard of carePatients diagnosed with deep vein thrombosis (DVT) and treated with rivaroxaban (Xarelto) were admitted to the hospital less frequently than those treated with the standard treatment of low-molecular-weight heparin (LMWH) and warfarin, according to real-world data presented at the Hospital Medicine 2015 Congress.
Oral anticoagulation may not help all AF patientsNew study finds that AF patients under 65 years of age but with a CHA2DS2-VASc score of 1 are unlikely to benefit from anticoagulation therapy.
VTE treatment regimens have similar outcomesHistorically, unfractionated heparin (UFH) with a vitamin K antagonist has been the standard treatment for deep venous thrombosis (DVT) or pulmonary embolism. More recently, low-molecular-weight heparin (LMWH) combined with vitamin K antagonists has become the most common choice, but newer target-specific oral anticoagulants have widened the range of treatment options.
FDA drug approvals - October 2014
FDA drug approvals - October 2014FDA actions in brief, fast-track designations, priority review.